title: The Aquamantys® system as alternative for parenchymal division and hemostasis in liver resection for hepatocellular carcinoma: a preliminary study.
abstract: OBJECTIVE
  To evaluate the clinical feasibility and safety of a new technique for liver resection using a new saline-coupled bipolar sealing device (Aquamantys®) that has shown high performance in the animal setting.
  
  
  METHODS
  Twelve Child-Pugh A cirrhotic patients with hepatocellular carcinoma underwent partial hepatectomies using Aquamantys®. Our primary end-point was to observe occurrence of early specific surgical complications as bleeding, biliary leakage and abscess development. Our secondary end-point was to evaluate local recurrence along resection margin after a minimum follow-up of 1 year.
  
  
  RESULTS
  One bisegmentectomy, five monosegmentectomies and six atypical resections were performed. Mean resection time was 45 minutes (range, 30-100 min). Mean blood loss was 20 mL (range 5-80 mL). Mean post-operative stay was 6 days (range 5-16 days). All specimens presented negative margins (R0) at pathological examination. No blood transfusion were required both intra-operatively and post-operatively. No mortality was observed within 30-days post-operatively. One fluid collection occurred after  6-7 bisegmentectomy and was successfully treated by ultrasound-guided percutaneous drainage. At 1 year follow-up two patients died: one because of new lesions into the liver and one because of distant metastases and multifocal new liver disease. Ten patient are alive disease free at 1 year follow-up.
  
  
  CONCLUSIONS
  Liver resection using Aquamantys® is feasible and safe and allows to achieve almost bloodless parenchymal division with minimal necrosis and negative margins even in atipycal resection. Comparative trials are needed to confirm our preliminary results.
authors.affiliation: Surgical Oncology Unit, University Hospital of Messina, Department of Human Pathology, University of Messina, Italy. currog@unime.it.
authors.forename: G
authors.initials: G
authors.lastname: Currò
authors.forename: S
authors.initials: S
authors.lastname: Lazzara
authors.forename: A
authors.initials: A
authors.lastname: Barbera
authors.forename: A
authors.initials: A
authors.lastname: Cogliandolo
authors.forename: A
authors.initials: A
authors.lastname: Dattola
authors.forename: M L
authors.initials: ML
authors.lastname: De Marco
authors.forename: E
authors.initials: E
authors.lastname: De Leo
authors.forename: V
authors.initials: V
authors.lastname: Rampulla
authors.forename: C
authors.initials: C
authors.lastname: Lazzara
authors.forename: G
authors.initials: G
authors.lastname: Navarra
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods*; D006801:Humans; D008103:Liver Cirrhosis / Q000473:pathology / Q000601:surgery*; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000601:surgery